Compounds for the reduction of beta-amyloid production
    3.
    发明授权
    Compounds for the reduction of beta-amyloid production 有权
    用于减少β-淀粉样蛋白生成的化合物

    公开(公告)号:US08604024B2

    公开(公告)日:2013-12-10

    申请号:US13477143

    申请日:2012-05-22

    摘要: Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: wherein X is selected from the group of CH2, O, and NR2; m=0 or 1; R1 at each instance is selected from the group of halogen, hydroxy, amino, C1-4alkylamino, C1-4dialkylamino, haloC1-4 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, and C2-C4 alkynyl; L is a bond, —NHCO—, —NH—, or L and Z together can be absent; Z is a C6-C10-aryl group or a 5-10 membered heterocyclic group which can be further substituted with from 0-3 substituents selected from the group of halogen, haloC1-4 alkoxy, 4-methoxyphenyl, hydroxy, amino, C1-4alkylamino, C1-4dialkylamino, haloC1-4 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, and C2-C4 alkynyl; R2 is selected from the group of hydrogen, benzyl, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, acetyl, and methanesulfonyl; and R3, R4 and R5 are independently selected from hydrogen or C1-4alkyl.

    摘要翻译: 包括其药学上可接受的盐的式(I)化合物在本文中阐述:其中X选自CH 2,O和NR 2; m = 0或1; 每个实例的R 1选自卤素,羟基,氨基,C 1-4烷基氨基,C 1-4二烷基氨基,卤代C 1-4烷基,CN,C 1 -C 6烷基或环烷基,C 1 -C 6烷氧基和C 2 -C 4炔基; L是键,-NHCO-,-NH-或L和Z可以不存在; Z是可以被0-3个选自卤素,卤代C 1-4烷氧基,4-甲氧基苯基,羟基,氨基,C 1 -C 10 - 芳基的取代基取代的C 6 -C 10 - 芳基或5-10元杂环基, C 1-4烷基氨基,卤代C 1-4烷基,CN,C 1 -C 6烷基或环烷基,C 1 -C 6烷氧基和C 2 -C 4炔基; R 2选自氢,苄基,C 1 -C 6烷基或环烷基,C 1 -C 6烷氧基,乙酰基和甲磺酰基; 并且R 3,R 4和R 5独立地选自氢或C 1-4烷基。

    COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION
    4.
    发明申请
    COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION 有权
    用于还原β-淀粉样生成的化合物

    公开(公告)号:US20130131051A1

    公开(公告)日:2013-05-23

    申请号:US13477143

    申请日:2012-05-22

    摘要: Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: wherein X is selected from the group of CH2, O, and NR2; m=0 or 1; R1 at each instance is selected from the group of halogen, hydroxy, amino, C1-4alkylamino, C1-4dialkylamino, haloC1-4 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, and C2-C4 alkynyl; L is a bond, —NHCO—, —NH—, or L and Z together can be absent; Z is a C6-C10-aryl group or a 5-10 membered heterocyclic group which can be further substituted with from 0-3 substituents selected from the group of halogen, haloC1-4 alkoxy, 4-methoxyphenyl, hydroxy, amino, C1-4alkylamino, C1-4dialkylamino, haloC1-4 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, and C2-C4 alkynyl; R2 is selected from the group of hydrogen, benzyl, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, acetyl, and methanesulfonyl; and R3, R4 and R5 are independently selected from hydrogen or C1-4alkyl.

    摘要翻译: 包括其药学上可接受的盐的式(I)化合物在本文中阐述:其中X选自CH 2,O和NR 2; m = 0或1; 每个实例的R 1选自卤素,羟基,氨基,C 1-4烷基氨基,C 1-4二烷基氨基,卤代C 1-4烷基,CN,C 1 -C 6烷基或环烷基,C 1 -C 6烷氧基和C 2 -C 4炔基; L是键,-NHCO-,-NH-或L和Z可以不存在; Z是可以被0-3个选自卤素,卤代C 1-4烷氧基,4-甲氧基苯基,羟基,氨基,C 1 -C 10 - 芳基的取代基取代的C 6 -C 10 - 芳基或5-10元杂环基, C 1-4烷基氨基,卤代C 1-4烷基,CN,C 1 -C 6烷基或环烷基,C 1 -C 6烷氧基和C 2 -C 4炔基; R 2选自氢,苄基,C 1 -C 6烷基或环烷基,C 1 -C 6烷氧基,乙酰基和甲磺酰基; 并且R 3,R 4和R 5独立地选自氢或C 1-4烷基。